Increased excitatory toxic signaling in neurons in the part of the brain controlling movement triggers the breakdown of cells long before any symptoms of amyotrophic lateral sclerosis (ALS) are noticed — at least in mice with ALS. The study, “Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43…
News
Patients with amyotrophic lateral sclerosis (ALS) have a different functional brain network than healthy individuals, and that difference appears to be strongly associated with disability, according to new research. This finding supports previous research suggesting that monitoring a patient’s brain for changes in its neuronal network can aid in evaluating ALS disability and likely disease progression. The study,…
The National Collegiate Athletic Association (NCAA) will honor Pete Frates, a former university baseball player who has amyotrophic lateral sclerosis (ALS), with its 2017 Inspiration Award for his perseverance, dedication and determination, and for being a role model and source of hope to others. The NCAA Honors Celebration will take place…
News
How Motor Neurons Form from Stem Cells Seen in Study That May Move ALS Cell Therapy Step Forward
The molecular steps taken to turn immature stem cells into working motor neurons were seen in new research, potentially furthering cell therapies to treat neurological disorders like amyotrophic lateral sclerosis (ALS) by teaching scientists more about this complex process. The study, “A Multi-Step Transcriptional And Chromatin State Cascade Underlies Motor Neuron Programming From Embryonic Stem Cells,” was published…
BrainStorm Cell Therapeutics recently presented data from its Phase 2 clinical trial, showing that the company’s NurOwn stem cells technology may halt disease progression in patients with amyotrophic lateral sclerosis (ALS). The data were presented at the 27th International Symposium on ALS/MND in Dublin, Ireland. The multi-center, randomized, double blind, placebo-controlled,…
A single-case study of a patient with amyotrophic lateral sclerosis (ALS) suggests that long-term invasive motor cortex stimulation via implants of electrodes may slow progression of the disease. The study, “Reduction of disease progression in a patient with amyotrophic lateral sclerosis after several years of epidural motor cortex stimulation” was published…
New types of genetically engineered mice that allow scientists to study brain cells called astrocytes are expected to advance the understanding of how the cells contribute to diseases such as amyotrophic lateral sclerosis (ALS). Inserting a gene sequence in a specific position makes it possible for researchers to turn a…
Cytokinetics recently presented patient baseline characteristics from its VITALITY-ALS clinical trial investigating Tirasemtiv for the treatment of amyotrophic lateral sclerosis (ALS). Data collected from an international physician survey on the use of noninvasive ventilation (NIV) in the treatment of ALS also was presented. Both presentations were made at the…
Origent Data Sciences and Cytokinetics reported results from the first part of a research partnership to further refine and validate an Origent’s computer model to predict amyotrophic lateral sclerosis (ALS) outcomes and disease progression. The effort’s ultimate goal is to develop models that can replace control arms, and the need for placebo…
The biopharma Neurimmune and the venture capital fund TVM Life Science Ventures VII announced they have created a Swiss company called AL-S Pharma AG to develop a new therapy for the treatment of amyotrophic lateral sclerosis (ALS). AL-S Pharma AG is a special purpose company formed to develop one compound — AP-101…
Recent Posts
- New collaboration targets protein buildup linked to brain diseases
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment